The subject has received bevacizumab for their disease unless in the context of primary therapy for newly diagnosed glioma

Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon stage, group, and age, as below

Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients

Group C: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma

Patients with newly diagnosed higher risk RCC of any histology including sarcomatoid or (if preoperative biopsy was uninformative) - “unknown” histology; RCC must have been confirmed by biopsy within 4 months prior to randomization; if the biopsy clearly demonstrated a benign condition or a different type of cancer, the patient is not eligible to be randomized

Newly diagnosed patients with histologically proven ALCL (International Classification of Diseases for Oncology [ICD-0] code: 9714/3)

Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or reverse transcriptase (RT)-PCR

The patient must have a newly diagnosed unifocal intracranial meningioma, gross totally resected, and histologically confirmed as WHO grade II based upon pathology findings at the enrolling institution; WHO grade will be assigned according to WHO 2016 criteria

Subject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naive

Patients with CNS GCTs who are newly diagnosed are excluded from the study

Newly-diagnosed brain cancer with histopathological diagnosis of GBM;

Participants must have histologically confirmed newly diagnosed glioblastoma or glioblastoma variant (example [ex.] gliosarcoma), including documentation of unmutated isocitrate dehydrogenase (IDH) by immunohistochemistry or sequencing

Patients must have a newly-diagnosed glioblastoma or gliosarcoma that has been confirmed pathologically by a board-certified neuropathologist

Newly diagnosed acute myeloid leukemia in older patients (>= 65 years) not candidates for intensive induction chemotherapy (Cohort 2)

Histologically confirmed newly diagnosed stage I-II HER2/neu positive breast cancer

Patients who have been diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease are not eligible; NOTE: patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

History of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor.

Newly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma

Be newly diagnosed and previously untreated

Diagnosed with APL-M3 or CBF-AML

Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia

Intrahepatic cholangiocarcinoma diagnosed by histology.

Prior WBRT for newly diagnosed brain metastases

Diagnosed with cervical esophageal carcinoma

Stratum B: Newly diagnosed children (3-21 years old) with diagnosis of glioma other than DIPG who are positive for the H3.3K27M mutation (positive testing in CLIA laboratory) including spinal cord gliomas that underwent standard radiation therapy

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of the study drugs or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Newly diagnosed neuroblastoma or ganglioneuroblastoma as verified by histology and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Treatment naive for his or her newly diagnosed malignancy for enrollment to groups 1 or 2

newly diagnosed AML unsuitable for intensive chemotherapy

Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years

Patients must be diagnosed with leptomeningeal carcinomatosis.

For the Phase II part of the study, newly diagnosed OR refractory/metastatic anaplastic thyroid cancer confirmed by histology, incurable by surgery, radiotherapy or chemoradiotherapy alone or in combination

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients diagnosed with primary CNS tumors

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Stratum VI -- Patients with newly diagnosed SS-LCH and localization other than \multifocal bone\,isolated tumorous CNS lesion, or isolated \CNS-risk\ lesion.

Patients must have a newly-diagnosed glioblastoma or gliosarcoma that has been confirmed pathologically

Newly diagnosed, previously untreated participants with rhabdomyosarcoma (RMS)

Diagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

No prior therapies are allowed for the treatment of the newly diagnosed breast cancer; patients with a prior diagnosis of malignancy treated >= 5 years ago are eligible, provided that they have not received prior taxanes or carboplatin as part of their prior treatment regimen, and that they meet all eligibility criteria

Patients with biopsy proven newly diagnosed rhabdomyosarcoma

Have newly diagnosed localized or locally advanced (T1N1-3M0 or T2-3NanyM0), potentially resectable disease without any prior systemic chemotherapy

Patients who have a history of another primary malignancy that has been diagnosed or required therapy within 3 years before randomization.

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Group 1: Must have newly diagnosed, pathologically confirmed cHL at Stages IA, IB and IIA without bulky disease. Group 2: Must have newly diagnosed, pathologically confirmed cHL at Stages IIEB, IIIEA,IIIEB, IIIB, IVA and IVB

Elderly (> 60 year old) patients with newly diagnosed AML not eligible for intensive chemotherapy

Newly diagnosed patients who are ineligible or declined to receive intensive chemotherapy after discussion of risks and benefits of that approach or patients with primary refractory/relapsed AML

Patients diagnosed with APL, AML-M3

Diagnosis or treated for another malignancy within 2 years before enrollment, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any time are not excluded if they have undergone resection

Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization.

Newly diagnosed brain cancer or tumor called glioblastoma or GBM

Newly-diagnosed brain cancer or tumor called glioblastoma or GBM

Other invasive cancers diagnosed < 3 years back that required systemic treatment; if diagnosed with other invasive cancer >= 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia

STRATUM A: Histological confirmation of a newly diagnosed high-grade glioma or DIPG

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection

Must have recurrent disease confirmed by MRI (Group 1) or completed SoC therapy such as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide according to local standards for newly diagnosed disease (Group 2)

Previously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Is diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease.

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Diagnosed with or treated for another malignancy within 2 years before randomization, or previously diagnosed with another malignancy and have any evidence of residual, persistent, or recurrent disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Have recurrent or refractory/unresectable disease for which there is no known curative therapy\r\n* Wild type-GIST: patients with recurrent or progressive disease will be eligible; newly diagnosed patients with resectable localized disease will not be eligible; newly diagnosed patients with metastatic disease and newly diagnosed patients with residual tumor following surgical debulking will be eligible\r\n* PHEO/PGL: patients with recurrent or progressive disease will be eligible; newly diagnosed patients with PHEO/PGL that is metastatic at diagnosis and/or unresectable will be eligible; patients with PHEO/PGL with localized (non-metastatic), resectable disease will not be eligible\r\n* Renal cell cancer associated with HLRCC: patients with localized, resectable HLRCC-associated renal cell cancer will not be eligible; patients with metastatic and/or unresectable HLRCC-associated renal cell cancer will be eligible

Newly diagnosed, untreated, biopsy proven non-small cell lung cancer

Patients with newly diagnosed, uncontrolled and or untreated cancer; related central nervous system diseases are excluded.

Newly diagnosed androgen-sensitive metastatic disease; or

Newly diagnosed, treatment naive, HNSCC suitable for surgical resection with planned radiotherapy and/or chemotherapy after surgery

Newly diagnosed histologically proven locoregional OCSCC (T-stage 2-4) without evidence of distant metastases; OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy =< 2 years prior to registration or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed, biopsy proven cancer of the endometrium, prostate or breast

Leptomeningeal carcinomatosis, diagnosed on cytology or appropriate imaging

Diagnosed with SMM within the last 4 years

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Subjects must be newly diagnosed or suspected to have breast, uterine (endometrial cancer with histologies including endometrioid, serous, clear cell, and carcinosarcoma) or cervical cancer

Histopathologically proven newly-diagnosed primary glioblastoma with complete or partial surgical resection; biopsy not acceptable

Current diagnosed neurologic disorder

Newly diagnosed de novo AML; or

Newly diagnosed AML patients who are identified with FLT3-ITD or tyrosine kinase domain (TKD) point mutation in the codon for an aspartate (D835) or an isoleucine (I836) residue

Newly diagnosed (non-M3) AML patients

No diagnosed arrhythmias

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Is currently participating or has participated in any other newly diagnosed therapeutic trial before or after chemoradiation

PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Has known gliomatous meningitis, extracranial disease, or multifocal disease

PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION AND IN NEWLY DIAGNOSED GBM: Has received prior therapy with any antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within five years of enrollment

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Histologically or cytologically confirmed newly diagnosed treatment-naive metastatic adenocarcinoma of the pancreas with metastatic disease diagnosed no more than 8 weeks prior to enrollment

Newly diagnosed or relapsed participants are eligible to participate; this protocol is intended to enroll both previously treated and untreated patients

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed, histologically proven (or strongly suspected, see below) T1-T2aN0M0 (Stage IA-IB) non-small cell lung cancer (NSCLC), with maximum tumor diameter =< 5 cm under consideration for stereotactic ablative body radiotherapy (SABR) as definitive primary treatment

Patient must be diagnosed with recurrent GBM either with biopsy or radiographically

Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment “wait and watch” or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkin’s lymphoma or CLL

Newly diagnosed, histologically confirmed breast cancer

Patients with newly diagnosed AT/RT

Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT

Patients with metastatic, surgically unresectable melanoma or newly diagnosed melanoma patients of any stage unable to receive or complete standard therapy

HER-2+ (HER2 status is not required for women diagnosed with DCIS)

Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0

Patient has newly diagnosed disease with no prior therapy

Patients must have undergone autologous stem cell transplantation, within 18 months of initiation of induction therapy for newly diagnosed myeloma

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with pathologically confirmed completely resected prostate cancer no higher than stage pT2a and no biochemical relapse, or pT2c tumors involving less than 5% of the prostate and no biochemical relapse, nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before study enrollment, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Currently receiving or scheduled to receive any other therapies intended to treat the newly diagnosed glioma prior to the MLA and the first post-MLA blood collection for correlative studies

Any prior treatment for the current, newly diagnosed breast cancer

Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed (> 2 years before study enrollment) with another malignancy and have any evidence of residual disease that is symptomatic or requiring treatment; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed acute lymphoblastic leukemia/lymphoma

Newly diagnosed histologically confirmed invasive breast cancer

Patient must have newly diagnosed, histologically confirmed GBM

Patients with newly diagnosed stage I and II nasal NK cell lymphoma

Four or more newly-diagnosed lesions

The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of stage I-IV (T1-3, N0-2b) of the oropharynx

In the phase II portion, patients must be newly diagnosed or treatment naive, or have been off adjuvant imatinib therapy for at least 3 months; patients with newly diagnosed GIST and who had been on imatinib for up to 4 weeks prior to signing the consent are allowed to enroll in order to expedite accrual

Newly diagnosed MCL: Confirmed diagnosis of MCL with CD20 and cyclin D1 positivity in tissue\r\nbiopsy; patients must have never received any prior therapy for their disease

Newly diagnosed MCL: Age > 65 years at the time of signing the informed consent

Newly diagnosed MCL: Patients should in general have bi-dimensional measurable disease with\r\ntheir biggest tumor less than 10 cm; (bone marrow or gastrointestinal [GI] only involvement is acceptable)

Newly diagnosed MCL: Serum bilirubin < 1.5 mg/dl

Newly diagnosed MCL: Ki67 protein (Ki67) < 50%

Newly diagnosed MCL: Patients must be willing to receive transfusions of blood products

Newly diagnosed MCL: Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty

Newly diagnosed MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient’s health and survival, than of the MCL, within the subsequent 6 months at the time of consent

Newly diagnosed MCL: Prior treatment with ibrutinib

Newly diagnosed MCL: Patients with blastoid and pleomorphic variants

Newly diagnosed MCL: Ki-67 to be equal or more than 50%

Newly diagnosed MCL: Central nervous system lymphoma

Newly diagnosed MCL: Patients with bi-dimensional measurable disease with a tumor >= 10 cm

Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront

Cohort A: newly diagnosed AML, no prior cytotoxic chemotherapy

Subjects who have been diagnosed with prior cancer at any site may participate as long as they have been off medical therapy for at least one year

Newly diagnosed, untreated intraocular retinoblastoma; participants previously diagnosed with unilateral retinoblastoma treated surgically, with focal therapy or needing chemotherapy who develop asynchronous involvement of the contralateral eye, or patients with unilateral retinoblastoma treated only with enucleation or focal therapy who develop asynchronous involvement of the contralateral eye, will be eligible for study

Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2

Untreated, non-transplant eligible, newly diagnosed mantle cell lymphoma with measurable disease as determined by computed tomography (CT), and bone marrow biopsy

Elderly subjects (? 65 years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy.

Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia

Patients with ICGCTs who are newly diagnosed are excluded from the study

Diagnosis of recurrent HL or NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory HL or NHL with a treatment plan that will include high dose therapy and stem cell transplantation

WHO grade I: tumor that are newly diagnosed and tumors that are incompletely excised; tumors that have recurred post resection

Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible

Newly diagnosed disease

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Diagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients diagnosed with hematological malignancies.

Has a newly diagnosed tumor and a curative treatment option or approved therapy is available

Patients diagnosed with another lung cancer subtype

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

newly diagnosed untreated AML in patients ? 65 years of age, if they are not candidates for standard available induction chemotherapy

Patients diagnosed with AML or MDS per below:

DCIS diagnosed with core biopsy

Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician.

Subjects diagnosed with other malignant primary tumor

Newly diagnosed DIPG patients\r\n* Patients must have not received any prior therapy for treatment of their current CNS malignancy other than radiation therapy

PART 2 PATIENTS (NEWLY DIAGNOSED GBM)

Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)

Diagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. \r\n* NOTE: Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinoma with or without ascites and potentially resectable disease agreeing to debulking surgery as standard therapy

Patients should be newly diagnosed HNSCC, with no prior therapy for this disease

History of metastatic cancer diagnosed less than 2 years prior to the first planned dose of PF-0444913

Diagnosed less than 3 years prior to entry on trial

Patients with newly diagnosed GCT

Newly diagnosed, previously untreated Diffuse Large B-Cell Lymphoma

Has had clinically diagnosed hepatic encephalopathy in the last 6 months.

Patient has been diagnosed and/or treated for any invasive cancer (other than study disease) less than 5 years prior to study enrollment.

A cancer diagnosed and definitively treated ? 5 years before randomization with no subsequent evidence of recurrence

Subject is diagnosed with colorectal cancer

newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy

Diagnosed or treated for another malignancy within 3 years (5 years for sites in France) before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Patients must have one of the following biopsy proven gynecological cancer and a decision to treat with radiotherapy and concurrent cisplatin chemotherapy (RT-CT)\r\n* Newly diagnosed epithelial carcinoma of the cervix, cT1B-3B, N0/1, M0/1\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed epithelial carcinoma of the upper 1/3 vagina, T1-3, N0/1, M0/1\r\n** Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control\r\n* Newly diagnosed endometrioid adenocarcinoma of the uterus, cT1-3, N0/1, M0 unsuitable for primary surgery because of the extent of local disease; these patients are eligible if a prior decision has been made to treat radically with neoadjuvant chemoradiation followed by surgery or further radiotherapy (including brachytherapy) depending on response\r\n* Central pelvis or sidewall recurrence of epithelial carcinoma of the cervix of endometrioid adenocarcinoma of the uterus after previous surgery without previous pelvic radiotherapy

T.Bili. ? 1.5 x ULN (except in patients diagnosed with Gilbert's disease).

Newly diagnosed participants who are considered appropriate candidates for comprehensive multimodality treatment (involving surgery and/or external beam radiotherapy or chemo radiotherapy).

Diagnosed with another malignancy within the past 3 years

Subjects ? 60 years of age with newly diagnosed AML

For carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma. For carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory disease

Patients must have newly diagnosed, untreated metastatic histologically or cytologically documented pancreatic adenocarcinoma; patients must not have known history of brain metastases

Patients with AML or RAEB 2 High Risk MDS who are newly diagnosed according to the WHO 2008 Classification and previously untreated.

Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have < 25% tumor cells in bone marrow by morphology)

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer, superficial bladder cancer, very low risk prostate on observation, or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.

Histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion

Newly (<6 months) diagnosed RCC (histological/cytological verification is optional) with at least one (1) CT-verified metastasis ?10mm for which complete metastasectomy is not planned. US patients must have verified clear-cell tumor histology

newly diagnosed advanced/metastatic breast cancer, treatment naïve

newly diagnosed advanced/metastatic breast cancer at diagnosis that progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor)

Patients must either not be a candidate for docetaxel chemotherapy for newly diagnosed metastatic prostate cancer, as determined by their treating oncologist, or have declined this therapy

Diagnosed with PNH

Known newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 3 months will be allowed to participate

Diagnosed or treated for another malignancy within 2 years before first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients must be newly diagnosed with de novo acute myelogenous leukemia

Patients must be newly diagnosed with histologically-proven hepatoblastoma

Newly diagnosed stage IIIA/B NSCLC, PS 0-1

Relapsed/refractory AML (>= 5% blasts in bone marrow or extramedullary leukemia) or newly diagnosed AML patients who are not candidates for (age >= 70 years; adverse cytogenetics, e.g., as defined by the Medical Research Council [MRC] Prognostic Groupings; secondary AML; organ dysfunction arising from significant co-morbidities not directly linked to leukemia; Eastern Cooperative Oncology Group [ECOG] = 2) or not willing to undergo intensive chemotherapy; Note that both relapsed/refractory and newly diagnosed AML patients will be eligible for the dose escalation part of the study, but only newly diagnosed patients will be eligible for the dose expansion cohort

Patients must not have received any prior treatment for current or newly diagnosed breast cancer

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed, biopsy-proven stage 0-II breast cancer

Patients taking aspirin for previously diagnosed cardiovascular disease

Patients diagnosed with advanced melanoma

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; male patients with incidental histological findings of prostate cancer (T1a or T1b using the TNM [tumor nodes, metastasis]) clinical staging system are not excluded

Is newly diagnosed with a curative treatment option available.

INCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG

EXCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG

Concurrent malignancy diagnosed within 6 months of entry to the study

Diagnosed or treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy with evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy with evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed with AML

Newly diagnosed elderly AML patients (> 60 years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients

Patients may either be untreated for their newly diagnosed metastatic disease (preferred as much as possible) or have started androgen deprivation therapy; patients who have started androgen deprivation therapy for the treatment of their newly diagnosed metastatic disease are eligible as long as the duration of treatment is less than or equal to 2 weeks (14 days) prior to registration; the start date of androgen deprivation is considered the day the patient first received an injection of a LHRH agonist/antagonist (or orchiectomy), not the date when an oral antiandrogen started

Patients who have received androgen deprivation therapy for greater than 14 days (LHRH-agonist or antagonist) for the treatment of their newly diagnosed metastatic disease prior to enrollment are not eligible for this study

Newly diagnosed or uncontrolled cancer-related central nervous system disease

COHORT A: The subject must have newly diagnosed prostate cancer with a metastatic site(s)

Prior malignancy except previously diagnosed and definitively treated more than 3 years prior to trial or whose prognosis is deemed good enough to not warrant surveillance

Subjects must be newly diagnosed or previously diagnosed with CNL or aCML; all patients must have a bone marrow biopsy completed during the screening or baseline period if one has not been done within 90 days of day 1, cycle one

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection

Subjects who have been diagnosed with indolent NHL that has progressed.

Diagnosed and treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients with newly diagnosed, CD30-positive mature T-cell lymphomas

Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme

Patient must have undergone autologous stem cell transplantation, with melphalan as a preparative regimen, within 12 months of initiation of induction therapy for newly diagnosed myeloma

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients with newly diagnosed PVNS with, at least, one measurable site of disease on MRI.

Pre- and post-menopausal women newly diagnosed with DCIS histologically confirmed on breast core biopsy

Newly diagnosed patients with no prior attempt at curative therapy

Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type were not excluded if they had undergone complete resection.

A tumor sample is required for enrollment (except for patients diagnosed > 7 years ago)

Newly diagnosed and confirmed Stage IIIB/IV NSCLC

Craniopharyngioma diagnosed by histology, cytology or neuroimaging

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed with another primary malignancy in the past 3 years

Newly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCT

Tumor: newly diagnosed non-disseminated diffuse intrinsic pontine glioma based on clinical AND radiographic finding

Histopathologically confirmed newly diagnosed glioblastoma multiforme; diagnosis must be made by surgical biopsy or excision

Male or female patient ? 18 years of age with newly diagnosed, histologically confirmed, AML including de novo, secondary to antecedent hematologic disorders, or treatment-related disease with intermediate or unfavorable-risk cytogenetics

Has newly diagnosed, locally advanced, centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

Patients must have 3 or fewer newly diagnosed metastatic lesions in the brain with a complete resection of at least one lesion as determined by the study neuroradiologist

Diagnosed with one of the following diseases:

Newly diagnosed, treatment naive CP-CML (Cohort 3)

Newly diagnosed disease

Newly diagnosed, AL amyloidosis treatment naïve

Patients who are newly diagnosed should have not received any other chemotherapeutic therapy (with the exception of dexamethasone) 1 week before starting, or radiation therapy, 4 weeks before starting

Patients must be ?1 and ? 21 years of age when originally diagnosed with ALL. Diagnosis

Evidence of another clinically or radiographically active invasive malignancy OR diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Patients with newly diagnosed double hit in first complete remission, anytime during the first 3 months after chemoimmunotherapy followed by autologous stem cell transplantation if there was no evidence of progression

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Biopsy-proven KS involving skin, with or without visceral involvement, either newly diagnosed or refractory to or intolerant of one or more prior therapies

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; this does not preclude previous diagnosis of acute myeloid leukemia or myelodysplastic syndrome

Subjects must have newly diagnosed (within 3 years), previously untreated prostate cancer without concurrent malignancy

Newly diagnosed untreated stage IV and/or recurrent after adjuvant therapy with metastatic disease

Newly diagnosed cGVHD defined by:

Diagnosis of AML or ALL, relapsed or refractory after at least 1 prior treatment regimen. Newly-diagnosed patients ? 60 years old who have refused or are considered unfit for standard chemotherapy regimens or stem cell transplantation are also eligible.

Have newly diagnosed or recurrent multi-focal Ta, large Ta, high grade Ta, carcinoma in situ (CIS) or T1 bladder cancer

Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 3 months will be allowed to participate

?18 years old, diagnosed with persistent or chronic ITP

Newly Diagnosed Secondary AML age <60 years and ?76 to 80 years, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)

Newly diagnosed inoperable cervical cancer treated with chemoradiation therapy with curative intent and life expectancy of at least 12 months as assessed by the investigator o No CNS/spinal metastases

Newly diagnosed patients with unilateral group D retinoblastoma

Patients must have newly diagnosed metastatic disease; note this may include non-measurable chest wall recurrence

Patients diagnosed with AML meeting one of the following criteria:\r\n* Newly diagnosed, age 60 and older\r\n* High risk cytogenetics and molecular abnormalities (National Comprehensive Cancer Network [NCCN] criteria)\r\n* Relapsed or refractory to prior chemotherapy\r\n* Secondary AML

PART II: Oncology participants must have histologically or cytologically diagnosed malignancy; ideally the subject has completed treatment within 6 months to a year and cancer is stable

If diagnosed with lung cancer, must have completed definitive treatment more than 6 months prior

Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of in situ malignancies

Newly diagnosed, previously untreated patients with histologically or molecularly confirmed Ewing sarcoma

Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases

Patients must have newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB to IV epithelial ovarian, fallopian tube, or peritoneal cancer and have recovered from debulking surgery.

Arm B: Patients with CML in AP or BP, either newly diagnosed or failing TKI therapy (i.e., Acute Group patients);

Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision

Documented evidence of symptomatic MM, either newly diagnosed or relapsed/refractory

Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ

Have either relapsed or refractory AML, or who have newly diagnosed Flt3-ITD positive AML but either refuse or are considered by the Investigator not to be an appropriate candidate for standard chemotherapy.

Is diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ

Patients diagnosed with hepatocellular carcinoma, or who have a history of biliary sepsis within the past 2 years

Patients diagnosed with alcoholism may not be treated with disulfiram

Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.

Newly Diagnosed Secondary AML defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)

Have newly diagnosed localized or locally advanced (T1N1-3M0 or T2-4NanyM0), potentially resectable disease without any prior systemic chemotherapy

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.

Patients must have a biopsy proven newly diagnosed locally confined, stage T1a, T2a or T2b prostate cancer

Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 6 months will be allowed to participate

Patients with 1-10 newly diagnosed brain metastases

Patients diagnosed with or treated for another malignancy within 2 years prior to study enrollment or previously diagnosed with another malignancy and still having any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Newly diagnosed cluster of differentiation (CD) 20+ DLBCL with IPI between 3-5

A parent (referred to as “parent” in this proposal and includes a parent or legal guardian) of a patient age 3 to 17 years of age who is newly diagnosed with any type of malignant disease on an inpatient oncology unit

The child must be a newly diagnosed patient with any type of malignant disease who will be or is receiving chemotherapy and/or radiation therapy

Patient must be newly diagnosed or relapsed/progressed with a brain tumor that has not previously been treated with CRT\r\n* Note: COG therapeutic study participation is not required for ACCL10P1 enrollment

Diagnosed with ALL

Individuals who have been diagnosed with lung cancer\r\n* Individuals are eligible regardless of date of diagnosis (newly diagnosed or long-term survivor), pathology type or stage of lung cancer, or history of other cancers

Newly diagnosed prostate cancer (PCa) (within 3-months).

Hospitalized patients with high-risk AML, defined as:\r\n* Newly diagnosed patients with AML \r\n* Newly diagnosed AML with antecedent hematologic disorder\r\n* Newly diagnosed therapy-related AML\r\n* Relapsed AML\r\n* Primary refractory AML

Newly diagnosed patients with stage 1 through 3a BC scheduled to receive a 12-week, 16-week, 18-week, 20- week, or 24-week chemotherapy regimen, adjuvant or neoadjuvant

Women histologically diagnosed with carcinoma of the breast

Bilateral disease (diagnosed cancer in both breasts)

Woman histologically diagnosed by an open biopsy procedure

Newly diagnosed and surgically treated females with stage I-III breast cancer

The patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma.

Patients diagnosed with T-cell Lymphomas.

Are newly diagnosed with prostate cancer

Women newly diagnosed (stage I-III) breast cancer

Newly diagnosed with stage I-III breast cancer

Have been diagnosed with lymphedema (LE) at least one year prior to study enrollment

Subjects must be diagnosed with differentiated thyroid cancer

Women newly diagnosed with stage I to III breast cancer who will be receiving adjuvant or neoadjuvant doxorubicin-based chemotherapy

Eligible patients must have been diagnosed with colon or rectal adenocarcinoma

Other cancers diagnosed within the last 5 years (in situ and/or invasive cancers)

Survivors who report ever being diagnosed with bipolar disorder will be excluded

Newly diagnosed solid tumor or lymphoma with histological verification

Has been diagnosed with psychotic, addictive, and major cognitive disorders

Patients who have ever been diagnosed with bipolar disorder or schizophrenia

Have a diagnosed malignancy

A newly diagnosed, histologically proven cancer arising from the oral cavity and oropharynx

SUBJECT: Children diagnosed with brain tumor in childhood.

Diagnosed with any solid or hematological cancer

Newly diagnosed, in need of a new line or therapy, or at a treatment decision making timepoint.

PATIENTS ONLY: Diagnosed with a primary glioma and going to receive at least 4 weeks of radiotherapy with at least 20 fractions

Patients who have ever been diagnosed with bipolar disorder or schizophrenia.

PATIENTS: Newly diagnosed with any stage cancer

Patient diagnosed with colorectal cancer

Have blood relatives diagnosed with ovarian cancer

Patients who are newly diagnosed with acute leukemia and hospitalized to receive their initial 4 weeks of intensive induction chemotherapy for this disease

Diagnosed cognitive impairment

Newly diagnosed with stage 2 or higher cervical cancer within the past 6 months

Newly diagnosed with any stage of uterine cancer (both sarcoma and carcinosarcoma) in the past 6 months

Be diagnosed with cancer

Newly diagnosed adult cancer patients from VICC and MMC or a participating caregiver designated by the patient

Patients diagnosed with a hematologic malignancy

Be diagnosed with bone metastases subsequent to breast (female subjects only) or prostate carcinoma, and will have received zoledronate or denosumab therapy for at least 3 months at the time of enrollment

Subject has previously been diagnosed with a serious immunodeficiency disorder.

Subjects with newly diagnosed stage I (T > 1 cm), II or III TNBC who have not undergone definitive breast surgery and have not received systemic chemotherapy will be eligible

Patient must be newly diagnosed (i.e., not relapsed) with any malignancy

Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)

Diagnosed with one or more metastatic brain tumor(s)

newly diagnosed with I-III non-metastatic cancer

Newly diagnosed with acute leukemia by pathology report

Newly diagnosed breast cancer (stage I, II, III)

Spouses of women with diagnosed within the past 8 months with stage III or IV ovarian cancer will be eligible to participate, as will the diagnosed wife/partner

Newly diagnosed with stage I-III breast cancer

Participants must be diagnosed with cancer

Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method

Newly diagnosed, primary, epithelial ovarian cancer

Diagnosed with operable invasive cancer

Newly diagnosed with a primary invasive endometrial cancer (any histology except sarcoma) and have a resection between 1/1/2013 and 12/31/2015 exclusively at Ohio State University (OSU)\r\n* For individuals who have neoadjuvant treatment and show a complete response at resection, the tumor screening will be attempted on their original biopsy (even if it occurred in 2012) as long as their resection occurred between 1/1/2013 and 12/31/2015

Were diagnosed with a childhood cancer prior to the age of 21 years

Patients diagnosed with any level of dysplasia on previous esophageal biopsies

Newly diagnosed breast cancer patients

Diagnosed or suspected vasospastic disease such as Raynaud’s syndrome;

Patient must be a newly diagnosed ALL, in first remission

All patients with newly diagnosed lymphoma

Diagnosed with osteoporosis

Newly diagnosed stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Women diagnosed with DCIS or ADH lesions detected by pathology

Patient is diagnosed with hematological malignancies including PTCL and CTCL and are eligible for treatment with a dose of 30 mg/m^2

Men newly diagnosed with prostate cancer who are scheduled for prostatectomy (stage T1 or T2)

Advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. Newly diagnosed patients who refuse standard treatment regimens are also eligible

Family history of CRC diagnosed before the age of 60 years

Previously diagnosed of ALL and currently in remission

Palpable abnormality diagnosed by core needle biopsy to be FEA or IPWA

The patient has diagnosed cancer of the cervix, vulva, or endometrium

Diagnosis of a proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor

Newly diagnosed tumors: patients with newly diagnosed grade IV glioma who have had not been previously treated with cranial radiation therapy

Be diagnosed with an adnexal mass

Newly diagnosed breast cancer patients

Newly diagnosed primary brain tumor of any location and any histology (Cohort 1)

Participants who are candidates for neoadjuvant chemotherapy or neoadjuvant endocrine therapy for the treatment of newly diagnosed, invasive breast cancer

Previously diagnosed high-grade tracheal obstruction

Patients must have histologically or cytologically proven advanced non-squamous NSCLC; patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spread

Participants must present with a gadolinium-enhancing brain lesion (or lesions) that are thought by the neuroradiologist and the neurosurgeon to be consistent with high-grade glioma; these may be newly diagnosed lesions or recurrent tumors

Patients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease)

Diagnosed with hypotonia

An adult patient with a newly diagnosed, untreated primary lung cancer diameter 7 mm or more; AND

Have one of the following disease histories: \r\n* Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \r\n** Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \r\n** Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n** Newly-diagnosed patients with previous excisional biopsy OR \r\n** Newly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated

MRI findings compatible with newly diagnosed or recurrent high- or low-grade malignant glioma

Patients diagnosed with anaplastic oligodendroglioma

Newly diagnosed, untreated mass in posterior fossa, either benign or malignant

Patients diagnosed with secondary hepatic malignancy

Newly-diagnosed or recurrent (local, regional, metastatic) metastatic melanoma or malignant brain tumor patients with:\r\n* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas, or malignant brain tumor\r\n* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n* Newly diagnosed patients with previous excisional biopsy

Have a previously diagnosed condition of dry mouth

Have a previously diagnosed condition of gum disease this included gingivitis, gingival bleeding and plaque

Patients will be eligible for this study regardless of prior treatment, as long as they meet other eligibility criteria; therefore, patients who are newly diagnosed, post-operative, post-radiation or post-chemotherapy are eligible

Newly diagnosed with esophageal cancer.

Patient is diagnosed with cancer

Be diagnosed with T1 or greater LABC, any N and M0.

Other malignancy diagnosed or requiring treatment within the defined period with specific exceptions

Patients with newly diagnosed and untreated stage II and II breast cancer scheduled to undergo neoadjuvant chemotherapy

Patients who will be undergoing surgery for newly-diagnosed glioblastoma

Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer

newly diagnosed glioblastoma or recurrent/suspected recurrent glioblastoma

Have newly diagnosed infiltrating ductal carcinoma of the breast

All cancer types and both newly diagnosed and previously treated patients will be included

Newly diagnosed with clinically node-negative breast cancer or melanoma being staged with SLN biopsy

Patients with newly diagnosed, relapsed, or refractory EBV-associated or KSHV-associated malignancies including human immunodeficiency virus (HIV)-associated lymphomas are potentially eligible

Men newly diagnosed with PCa who are scheduled for radical prostatectomy (RP) (stage T1 or T2)

Diagnosed with pancreatic cancer and scheduled to undergo surgery

Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Hospitalized for newly diagnosed acute leukemia

Study Arm 2: Patients previously diagnosed with a non-mucinous epithelial ovarian carcinoma (including serous, clear cell, and endometrioid histologies as well as borderline ovarian tumors) currently undergoing routine surveillance for recurrence, having been diagnosed with recurrence but prior to initiation of chemotherapy; patients from Study Arm 1 will automatically be included in Study Arm 2 as well unless they withdraw consent; finally, patients who have been diagnosed with an ovarian cancer of acceptable histology, who have already undergone surgery or biopsy, but not yet initiated adjuvant chemotherapy are eligible for Study Arm 2

Be diagnosed with a neurodegenerative disease

Diagnosed alcoholism within the last 5 years

Providing surgical treatment for newly diagnosed breast cancer patients

PHASE II: Women newly diagnosed with breast cancer on the day they meet with their surgeon for their initial consultation after the visit

Newly diagnosed breast cancer

Newly diagnosed suspected or proven clinical stage I NSCLC (T1 or T2, N0, M0) with no prior treatment for this disease

Active substance use disorder (diagnosed or strongly suspected) (Arm 4)

Ever diagnosed with lung cancer

Diagnosed with non-metastatic (i.e., stages I – III) cancer

History of treatment for cancer or related illness diagnosed at =< 25 years old

Diagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Patients diagnosed with bladder cancer with planned cystectomy and urinary diversion, +/- neoadjuvant chemotherapy

Histologically confirmed newly diagnosed G4 MG

Patients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be 60 years of age or older

Newly diagnosed, de novo or secondary, previously untreated AML

Participants must have progressive, advanced cancer as defined by one of the following:\r\n* Newly diagnosed, untreated advanced disease\r\n* Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed)\r\n* Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment; any number of prior therapies are acceptable excluding previous EGFR kinase inhibitors

Diagnosed with meningeal carcinomatosis.

has been diagnosed less than 3 months before study entry and/or